The discontinuation of the Fleming fund: Implications for global mitigation of antimicrobial resistance

Dear Editor,

We write with profound concern, regarding the recent reports of the discontinuation of the UK's Fleming Fund, a landmark initiative and innovation in the global effort against the scourge of antimicrobial resistance (AMR) that has had adverse effects on collective global health. As detailed in The Telegraph, this £265 million program—established in 2015 to honor Sir Alexander Fleming's legacy—has been halted due to governmental aid reductions [1].

The discontinuation, amid broader aid cuts, represents more than a fiscal decision; it is an act that undermines decades of progress against antimicrobial resistance.

Given the fund's critical role in supporting laboratory capacity and surveillance in low- and middle-income countries (LMICs) where the majority is found in regions like the MENA(Middle East and North Africa) and the Subsaharan [2], this development warrants urgent attention from microbiologists, clinicians, public health practitioners, policymakers and the community of universal healthcare advocates.

As we all know, antimicrobial resistance is an all-encompassing problem facing every sphere of antimicrobial control measures be it in the lab, in the clinics and in the ginormous healthcare facilities. Prior to this economically shortsighted move, The Fleming fund represented a model of evidence-based global health governance.

It is a life-saving initiative tackling antimicrobial resistance (AMR) by strengthening laboratories, building human capacity, integrating data ecosystems, and promoting a One Health approach that links human, animal, and environmental AMR surveillance, ultimately generating critical data to inform AMR mitigation efforts.

It directly addressed the 2014 UK Review on AMR (O'Neill Commission), which projected 10 million annual AMR-related deaths by 2050 without intervention [3]. By strengthening diagnostic capabilities in over 200 laboratories across 25 LMICs, the fund enabled [3,4]:

• 1.Standardized surveillance of resistant pathogens, aligning with WHO GLASS priorities;
• 2.Capacity-building for local microbiologists and lab technicians;
• 3.Data-driven policymaking supporting 170+ national AMR action plans.

Therefore, its foreclosure risks reversing gains in regions where AMR surveillance remains critically underfunded, undermanned and under-resourced.

Furthermore, there are broader implications for global health. AMR's cross-border nature makes this decision consequential beyond LMICs:

• -Global Health Security: Resistant pathogens from under-monitored regions threaten all health systems. The UK itself faces a high toll of AMR-implicated deaths annually [1].
• -Economic Costs: The World Health Organisation estimates that AMR could cost global healthcare systems $1.1 trillion yearly by 2050 [5], which far exceeds the Fleming fund's total budget.
• -Equity in research: The fund empowered LMIC researchers to contribute data to global AMR databases. Its absence exacerbates inequities in research, scientific grit and pandemic preparedness.

While acknowledging fiscal constraints faced by governments — internally and externally, we respectfully suggest:

• 1.Transitional Support: A phased and systematic withdrawal process allowing partners to secure alternative funding and/or facilitate indigenous or nationalistic funding
• 2.Multilateral Coordination: Redirecting efforts through WHO or the Global AMR R&D Hub
• 3.Private-Sector Engagement: Leveraging the fund's infrastructure for public-private partnerships.

The Fleming Fund exemplified the UK's leadership in translating AMR research into actionable policy. We hope its closure sparks renewed dialogue on sustainable financing mechanisms for AMR—a challenge requiring shared responsibility across scientific, political, and economic spheres.

CRediT authorship contribution statement

Patrick Ashinze: Conceptualization, Data curation, Supervision, Validation, Visualization. Oluwadamilare Olatunbosun: Writing – review & editing. Jasmine Kaur: Writing – review & editing. Maryam Olabisi Atofarati: Writing – review & editing. Abba Owoicho: Writing – review & editing. Toniloba Akingbola: Writing – review & editing. Daniel Olumuyiwa Ogunruku: Writing – review & editing. Folayemi Abiodun Iwaloye: Writing – review & editing.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Funding

Not applicable.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Handling Editor: Patricia Schlagenhauf